Korean J Perinatol.  2014 Dec;25(4):235-245. 10.14734/kjp.2014.25.4.235.

Antepartum Use of Antibiotics

• Cha HH

• KMID: 2281141
• DOI: http://doi.org/10.14734/kjp.2014.25.4.235

Abstract

Antibiotics are among the most commonly prescribed medicines during pregnancies for various reasons. The antepartum use of antibiotics requires the consideration of maternal physiologic change, its effects to fetuses and drug-resistance. Usually, antibiotics are prescribed to pregnant women complicated with preterm labor, preterm premature ruptures of the membranes, urinary tract infection or sexually transmitted diseases. In this article, we reviewed the antepartum use of antibiotics in obstetrical management.

Keyword

Antibiotics; Pregnancy; Preterm labor; Preterm premature rupture of the membranes; Sexually transmitted disease

MeSH Terms

Anti-Bacterial Agents*
Female
Fetus
Humans
Membranes
Obstetric Labor, Premature
Pregnancy
Pregnant Women
Rupture
Sexually Transmitted Diseases
Urinary Tract Infections
Anti-Bacterial Agents

Reference

1.Nahum GG., Uhl K., Kennedy DL. Antibiotic use in pregnancy and lactation: what is and is not known about teratogenic and toxic risks. Obstet Gynecol. 2006. 107:1120–38.

2.Nicolle LE. Use of Antimicrobials during pregnancy. Can Fam Physician. 1987. 33:1247–51.

3.Costantine MM. Physiologic and pharmacokinetic changes in pregnancy. Front Pharmacol. 2014. 5:65.

4.de Tejada BM. Antibiotic use and misuse during pregnancy and delivery: benefits and risks. Int J Environ Res Public Health. 2014. 11:7993–8009.

5.Bassetti M., Merelli M., Temperoni C., Astilean A. New antibiotics for bad bugs: where are we? Ann Clin Microbiol Antimicrob. 2013. 12:22.

6.Crider KS., Cleves MA., Reefhuis J., Berry RJ., Hobbs CA., Hu DJ. Antibacterial medication use during pregnancy and risk of birth defects: National Birth Defects Prevention Study. Arch Pediatr Adolesc Med. 2009. 163:978–85.

7.Cunningham FG., Leveno KJ., Bloom SL., Spong CY., Dashe JS., Hoffman BL, et al. Williams Obstetrics. 24th ed.McGraw Hill;2014. p. 248.

8.Bar-Oz B., Moretti ME., Boskovic R., O'Brien L., Koren G. The safety of quinolone-a meta-analysis of pregnancy outcomes. Eur J Obstet Gynecol Reprod Biol. 2009. 143:75–8.

9.Leppaluoto PA. Bacterial vaginosis: what is physiological in vaginal bacteriology? An update and opinion. Acta Obstet Gynecol Scand. 2011. 90:1302–6.

10.Brocklehurst P., Gordon A., Heatley E., Milan SJ. Antibiotics for treating bacterial vaginosis in pregnancy. Cochrane Database Syst Rev. 2013. 1:CD000262.

11.Leitich H., Bodner-Adler B., Brunbauer M., Kaider A., Egarter C., Husslein P. Bacterial vaginosis as a risk factor for preterm delivery: a meta-analysis. Am J Obstet Gynecol. 2003. 189:139–47.

12.Workowski KA., Berman S. Sexually transmitted diseases treatment guidelines, 2010. MMWR Recomm Rep. 2010. 59:1–110.

13.Odendaal HJ., Popov I., Schoeman J., Smith M., Grove D. Preterm labour-is bacterial vaginosis involved? S Afr Med J. 2002. 92:231–4.

14.Hauth JC., Goldenberg RL., Andrews WW., DuBard MB., Copper RL. Reduced incidence of preterm delivery with metronidazole and erythromycin in women with bacterial vaginosis. N Engl J Med. 1995. 333:1732–6.

15.Morales WJ., Schorr S., Albritton J. Effect of metronidazole in patients with preterm birth in preceding pregnancy and bacterial vaginosis: a placebo-controlled, double-blind study. Am J Obstet Gynecol. 1994. 171:345–7.

16.McDonald HM., O'Loughlin JA., Vigneswaran R., Jolley PT., Harvey JA., Bof A, et al. Impact of metronidazole therapy on preterm birth in women with bacterial vaginosis flora (Gardnerella vaginalis): a randomised, placebo controlled trial. Br J Obstet Gynaecol. 1997. 104:1391–7.

17.Leitich H., Brunbauer M., Bodner-Adler B., Kaider A., Egarter C., Husslein P. Antibiotic treatment of bacterial vaginosis in pregnancy: a meta-analysis. Am J Obstet Gynecol. 2003. 188:752–8.

18.U.S. Preventive Services Task Force. Screening for bacterial vaginosis in pregnancy to prevent preterm delivery: U.S. Preventive Services Task Force recommendation statement. Ann Intern Med. 2008. 148:214–9.

19.Taylor-Robinson D. Mycoplasma genitalium -- an up-date. Int J STD AIDS. 2002. 13:145–51.

20.Taylor-Robinson D. The role of mycoplasmas in pregnancy outcome. Best Pract Res Clin Obstet Gynaecol. 2007. 21:425–38.

21.Taylor-Robinson D., Lamont RF. Mycoplasmas in pregnancy. BJOG. 2011. 118:164–74.

22.Capoccia R., Greub G., Baud D. Ureaplasma urealyticum, Mycoplasma hominis and adverse pregnancy outcomes. Curr Opin Infect Dis. 2013. 26:231–40.

23.Pararas MV., Skevaki CL., Kafetzis DA. Preterm birth due to maternal infection: Causative pathogens and modes of prevention. Eur J Clin Microbiol Infect Dis. 2006. 25:562–9.

24.Ogasawara KK., Goodwin TM. The efficacy of prophylactic erythromycin in preventing vertical transmission of Ureaplasma urealyticum. Am J Perinatol. 1997. 14:233–7.

25.Mabanta CG., Pryhuber GS., Weinberg GA., Phelps DL. Erythromycin for the prevention of chronic lung disease in intubated preterm infants at risk for, or colonized or infected with Ureaplasma urealyticum. Cochrane Database Syst Rev. 2003. CD003744.

26.Raynes Greenow CH., Roberts CL., Bell JC., Peat B., Gilbert GL., Parker S. Antibiotics for ureaplasma in the vagina in pregnancy. Cochrane Database Syst Rev. 2011. 7:CD003767.

27.Samra Z., Rosenberg S., Dan M. Susceptibility of Ureaplasma urealyticum to tetracycline, doxycycline, erythromycin, roxithromycin, clarithromycin, azithromycin, levofloxacin and moxifloxacin. J Chemother. 2011. 23:77–9.

28.Witt A., Sommer EM., Cichna M., Postlbauer K., Widhalm A., Gregor H, et al. Placental passage of clarithromycin surpasses other macrolide antibiotics. Am J Obstet Gynecol. 2003. 188:816–9.

29.Guinto VT., De Guia B., Festin MR., Dowswell T. Different antibiotic regimens for treating asymptomatic bacteriuria in pregnancy. Cochrane Database Syst Rev. 2014. 8:CD007855.

30.Schnarr J., Smaill F. Asymptomatic bacteriuria and symptomatic urinary tract infections in pregnancy. Eur J Clin Invest. 2008. 38(Suppl 2):50–7.

31.U.S. Preventive Services Task Force. Screening for asymptomatic bacteriuria in adults: reaffirmation recommendation statement. Am Fam Physician. 2010. 81:505.

32.National Collaborating Centre for Women's and Children's Health. Antenatal Care: Routine care for the healthy pregnant woman. London: RCOG Press;2008.

33.Cunningham FG., Leveno KJ., Bloom SL., Spong CY., Dashe JS., Hoffman BL, et al. Williams Obstetrics. 24th ed.McGraw Hill;2014. p. 1053.

34.Kazemier BM., Schneeberger C., De Miranda E., Van Wasse-naer A., Bossuyt PM., Vogelvang TE, et al. Costs and effects of screening and treating low risk women with a singleton pregnancy for asymptomatic bacteriuria, the ASB study. BMC Pregnancy Childbirth. 2012. 12:52.

35.American College of Obstetricians and Gynecologists Committee on Obstetric Practice. ACOG Committee Opinion No. 494: Sulfonamides, nitrofurantoin, and risk of birth defects. Obstet Gynecol. 2011. 117:1484–5.

36.Pammi M., Garley JE., Carlin EM. Pregnancy outcomes of HIV-positive women in a tertiary centre in the UK. J Obstet Gynaecol. 2014. 11:1–3.

37.The panel on Treatment of HIV-infected woman and Prevention of Perinatal Transmission. Recommendations for use of antiretroviral drugs in pregnant HIV-1 infected women for maternal health and interventions to reduce perinatal HIV transmission in the United States. Available at:. http://aidsin-fonihgov/contentfiles/lvguidelines/PerinatalGL/pdf2012.

38.Kim T. Treatment and management of Sexually Transmitted Diseases. J Korean Med Assoc. 2008. 51:884–96.

39.Chisholm CA., Katz VL., McDonald TL., Bowes WA Jr. Penicillin desensitization in the treatment of syphilis during pregnancy. Am J Perinatol. 1997. 14:553–4.

40.Centers for Disease Control and Prevention. Update to CDC's Sexually transmitted diseases treatment guidelines, 2010: oral cephalosporins no longer a recommended treatment for gonococcal infections. MMWR Morb Mortal Wkly Rep. 2012. 61:590–4.

41.Silver BJ., Guy RJ., Kaldor JM., Jamil MS., Rumbold AR. Trichomonas vaginalis as a cause of perinatal morbidity: a systematic review and meta-analysis. Sex Transm Dis. 2014. 41:369–76.

42.Burtin P., Taddio A., Ariburnu O., Einarson TR., Koren G. Safety of metronidazole in pregnancy: a meta-analysis. Am J Obstet Gynecol. 1995. 172:525–9.

43.Romero R., Mazor M. Infection and preterm labor. Clin Obstet Gynecol. 1988. 31:553–84.

44.Ovalle A., Martinez MA., Gomez R., Saez J., Menares I., As-pillaga C, et al. Premature labor with intact membranes: microbiology of the amniotic fluid and lower genital tract and its relation with maternal and neonatal outcome. Rev Med Chil. 2000. 128:985–95.

45.Gibbs RS., Romero R., Hillier SL., Eschenbach DA., Sweet RL. A review of premature birth and subclinical infection. Am J Obstet Gynecol. 1992. 166:1515–28.

46.Yoon BH., Romero R., Moon JB., Shim SS., Kim M., Kim G, et al. Clinical significance of intra-amniotic inflammation in patients with preterm labor and intact membranes. Am J Obstet Gynecol. 2001. 185:1130–6.

47.Kenyon SL., Taylor DJ., Tarnow-Mordi W. ORACLE Collaborative Group. Broad-spectrum antibiotics for spontaneous preterm labour: the ORACLE II randomised trial. ORACLE Collaborative Group. Lancet. 2001. 357:989–94.

48.Kenyon S., Pike K., Jones DR., Brocklehurst P., Marlow N., Salt A, et al. Childhood outcomes after prescription of antibiotics to pregnant women with spontaneous preterm labour: 7-year follow-up of the ORACLE II trial. Lancet. 2008. 372:1319–27.

49.American College of Obstetricians and Gynecologists. ACOG Practice Bulletin No. 120: Use of prophylactic antibiotics in labor and delivery. Obstet Gynecol. 2011. 117:1472–83.

50.American College of Obstetricians and Gynecologists; Committee on Practice. ACOG practice bulletin no. 127: Management of preterm labor. Obstet Gynecol. 2012. 119:1308–17.

51.Russell AR., Steer PJ. Antibiotics in preterm labour--the ORACLE speaks. Lancet. 2008. 372:1276–8.

52.Ovalle A., Romero R., Gomez R., Martinez Mam., Nien JK., Ferrand P, et al. Antibiotic administration to patients with preterm labor and intact membranes: is there a beneficial effect in patients with endocervical inflammation? J Matern Fetal Neonatal Med. 2006. 19:453–64.

53.DiGiulio DB., Romero R., Kusanovic JP., Gomez R., Kim CJ., Seok KS, et al. Prevalence and diversity of microbes in the amniotic fluid, the fetal inflammatory response, and pregnancy outcome in women with preterm pre-labor rupture of membranes. Am J Reprod Immunol. 2010. 64:38–57.

54.Kenyon SL., Taylor DJ., Tarnow-Mordi W. ORACLE Collaborative Group. Broad-spectrum antibiotics for preterm, prelabour rupture of fetal membranes: the ORACLE I randomised trial. Lancet. 2001. 357:979–88.

55.Mercer BM., Miodovnik M., Thurnau GR., Goldenberg RL., Das AF., Ramsey RD, et al. Antibiotic therapy for reduction of infant morbidity after preterm premature rupture of the membranes. A randomized controlled trial. National Institute of Child Health and Human Development Maternal-Fetal Medicine Units Network. JAMA. 1997. 278:989–95.

56.Mercer B. Antibiotics in the management of PROM and Pre-term labor. Obstet Gynecol Clin N Am. 2012. 39:65–76.

57.Kenyon S., Pike K., Jones DR., Brocklehurst P., Marlow N., Salt A, et al. Childhood outcomes after prescription of antibiotics to pregnanty women with preterm rupture of the membrantes: 7-year follow-up of the ORACLE I trail. Lacet. 2008. 372:1310–8.

58.Yudin MH., van Schalkwyk J., Van Eyk N., Boucher M., Castillo E., Cormier B, et al. Society of Obstetricians and Gynaecologists of Canada. Antibiotic therapy in preterm premature rupture of the membranes. J Obstet Gynaecol Can. 2009. 31:863–7.

59.American College of Obstetricians and Gynecologists. Practice bulletins No. 139: premature rupture of membranes. Obstet Gynecol. 2013. 122:918–30.

60.Kenyon S., Boulvain M., Neilson JP. Antibiotics for preterm rupture of membranses. Cochrane Database Syst Rev. 2013. 12:CD001058.

61.Kwak HM., Shin MY., Cha HH., Choi SJ., LEE JH., Kim JS, et al. The efficacy of cefazolin plus macrolide (erythromycin or clarithromycin) versus cefazolin alone in neonatal morbidity and placental inflammation for women with preterm premature rupture of membranes. Placenta. 2013. 34:346–52.

62.Park HS., Ahn BJ., Kwan Jun J. Placental transfer of clarithromycin in human pregnancies with preterm premature rupture of membranes. J Perinatal Med. 2012. 40:641–6.